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Objectives: The aim of this study was to develop and apply an instrument to map the level of health technology assessment (HTA) development at country level in selected countries. We examined
middle-income countries (Argentina, Brazil, India, Indonesia, Malaysia, Mexico, and Russia) and countries well-known for their comprehensive HTA programs (Australia, Canada, and United Kingdom).
Methods: A review of relevant key documents regarding the HTA process was performed to develop the instrument which was then reviewed by selected HTAi members and revised. We identified and
collected relevant information to map the level of HTA in the selected countries. This was supplemented by information from a structured survey among HTA experts in the selected countries (response
rate: 65/385).
Results: Mapping of HTA in a country can be done by focusing on the level of institutionalization and the HTA process (identification, priority setting, assessment, appraisal, reporting, dissemination,
and implementation in policy and practice). Although HTA is most advanced in industrialized countries, there is a growing community in middle-income countries that uses HTA. For example, Brazil is
rapidly developing effective HTA programs. India and Russia are at the very beginning of introducing HTA. The other middle-income countries show intermediate levels of HTA development compared
with the reference countries.
Conclusions: This study presents a set of indicators for documenting the current level and trends in HTA at country level. The findings can be used as a baseline measurement for future monitoring and
evaluation. This will allow a variety of stakeholders to assess the development of HTA in their country, help inform strategies, and justify expenditure for HTA.
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A systematic evaluation of the level and trends in development
of health technology assessment (HTA) is lacking. Previous
studies generally focus on the best way to perform HTA (1).
These include initiatives that aim to support the development
of co-operation among HTA institutions such as Eur-Assess
(1994–97), HTA Europe (1997–99), ECHTA/ECHAHI (Eu-
ropean Collaboration for Assessment of Health Interventions)
project (1999–01), EUnetHTA Project (2006–08), EUnetHTA
Collaboration (2008–09), EUnetHTA Joint Action 1 (2010–
12), and the International Network of Agencies for HTA (IN-
AHTA). For example, the ECHTA/ECHAHI project developed
a best practice of the HTA process based on well-recognized
and internationally agreed characteristics along with a com-
mon understanding of the HTA process (2;3). This guidance
was further developed and implemented in the EUnetHTA Col-
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laboration and its successors, EUnetHTA Joint Action 1 and 2
(4).
Complementary to these initiatives, the objective of our
study was to develop and apply an instrument to map the level
of HTA at country level in selected countries.
METHODS
Development and Adjustment of the Instrument
In developing the instrument we distinguished two key elements
of HTA: (i) the institutionalization of HTA and (ii) the HTA
process itself.
The main sources used include EUnetHTA tools such as the
Handbook on Health Technology Assessment Capacity Build-
ing (3), the report on best practice in undertaking and reporting
HTA of the ECHTA/ECHAHI project (5), guidance of the In-
ternational Information Network on New and Changing Health
Technologies (EuroScan) regarding effective early warning sys-
tems (6), the INAHTA checklist to present HTA information (7)
and the principles for HTA programs in different countries of
the International Working Group for HTA Advancement (8).
The draft instrument consisted of the following domains:
(i) institutionalization of HTA; (ii) identification; (iii) prior-
ity setting; (iv) assessment; (v) appraisal; (vi) reporting; (vii)
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dissemination; and (viii) implementation of HTA in policy and
practice. The categories ii–viii have been used in the EUnetHTA
Collaboration to describe the HTA process (5).
For each domain a set of criteria was determined along
with indicators on how to measure each criterion using the key
documents stated above. For example, an indicator for institu-
tionalization is membership of the international society for the
promotion of HTA (HTAi) and membership of INAHTA. The
latter requires that the agency is not-for-profit, funded at least
50 percent from public sources and has a national / regional
function (3). However, not all countries have formal HTA pro-
grams in place. We therefore added two indicators that reflect a
less well institutionalized situation. In addition, a simple scor-
ing system for each criterion was developed consisting of a
grading scale that differentiates between the different levels of
HTA development in a country. For example, we decided that
an established agency that is a member of INAHTA reflects a
more institutionalized level of HTA than a government-advising
group outside INAHTA or the presence of elements to estab-
lish a (formal) HTA program if no agency or group is in place.
Therefore, the score of a country with at least one national or
regional agency/organization that is a member of INAHTA is
higher (25) than the score of a country without a formal HTA
program (i.e., a government-advising group outside INAHTA
(score: 20) or no agency or group but elements of establishing
a formal program are in place (score: 24 at the maximum) (see
Table 1).
The instrument was adjusted by asking HTA experts with
a strong interest in middle-income countries to give feedback.
First, the instrument was sent by email to members (n = 75)
of the interest sub-group on HTA in developing countries of
HTAi (HTAi DC ISG) in June 2011. Second, the attendees
(approximately 25) of the HTAi DC ISGmeeting in Brazil (July
2011) were asked to review the instrument. Third, we asked a
small sample of active HTAimembers (n= 10), includingHTAi
DC ISG members as reviewers. In total, we received comments
from six experts: two from India, two from Australia, one from
China, and one from Poland. The respondents are well-known
HTA experts in their respective countries. Their comments were
used in developing the final version of the instrument.
Selection of Countries
To identify middle-income countries, we used the definition
of the World Bank. Lower-middle-income countries are de-
fined as countries with GDP/capita between $1,006 and $3,975
and upper-middle-income countries range between $3,975 and
$12,275 (9). We aimed to include countries from different re-
gions (Latin America and the Caribbean, Asia, and Europe) that
undertake, according to our experience and knowledge at the
start of the study, different levels of HTA activities. Argentina,
Brazil (recently well developed HTA systems), Malaysia, Mex-
ico (moderately developed HTA systems), India, Indonesia, and
Russia (no or some elements of HTA systems in place) were
selected.
For benchmarking purposes three reference countries with
well developed HTA systems from different regions (Asia-
Pacific, North America, and Europe) were selected, namely,
Australia, Canada, and the United Kingdom (England and
Wales). These countries are often used in international com-
parisons of HTA systems.
Document Review
To map the level of HTA relevant information from the (gray)
literature for each country was collected and reviewed. For
some countries we had collected information in a previous
study on the role of HTA in middle-income countries, including
Argentina, Brazil, and Mexico (10). In the current study we
used the same search strategy as published in 2010, avoiding
overlap and duplication to the maximum. In addition, multi-
ple databases were searched (World Health Organization, Euro-
peanObservatory onHealth Systems and Policies, Organization
for Economic Cooperation and Development, World Bank, and
PubMed/Medline) to identify recent publications. Also, the In-
ternational Journal of Technology Assessment in Health Care
was searched for relevant articles. We used the following search
terms: <country> AND health system OR healthcare system;
health insurance; reimbursement of pharmaceuticals; and health
technology assessment. Searches were limited to publications
from 2000 to 2011 (inclusive) that are available in English and in
the public domain. Moreover, an Internet-based review of wider
information sources was performed (i.e., professional organiza-
tions at international level: INAHTA, HTAi, and International
Society for Pharmacoeconomics and Outcomes Research re-
garding specific information on the selected countries) using
the same search terms. Reference lists of retrieved documents
have been hand searched to identify additional publications of
interest. Articles or information that were targeted at either the
institutionalization ofHTAor elements of theHTAprocesswere
included in the study.
Web-Based Survey
A Web-based survey (in English) was distributed to key HTA
experts in the selected countries. The survey consisted of forty-
four close-ended and open-ended questions focusing on the
main domains of the instrument. The final two sections of the
survey provided opportunities for further comments on future
developments regarding HTA in their country, as well as general
comments on the survey.
Before launch the survey was piloted with two potential
respondents (one from a middle-income country and one from
a reference country) to ensure that it functioned properly from a
technical point of view, as well as to confirm that the questions
could be understood and were relevant. Some revisions were
made after this step.
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Table 1. The Mapping Instrument
Domain: Institutionalization
Criterion: Level of institutionalisation
Indicators: Score (on country level)
At least 1 national or regional agency/organisation that is a member of INAHTA (since. . .) and a) reports to a Minister of Health/human
resources or other authorities such as social security institutions; b) produces and/or endorses HTA reports and c) informs decisions about
introduction, reimbursement and disinvestment from health technologies.
[Please note that a country might have several agencies that are member of INAHTA, e.g. the Netherlands, Spain] – the requirement for
becoming an INAHTA member is to have at least 50% public funding
Yes = 25
No = 0
At least 1 government-advising group outside INAHTA and a) reports to a Minister of Health/human resources or other authorities such as social
security institutions; b) produces and/or endorses HTA reports and c) informs decisions about introduction, reimbursement and disinvestment
from health technologies.
Yes = 20
No = 0
Presence of fulfilment of elements needed to establish a (formal) HTA programme if no agency or group is in place:
• Interest in HTA expressed by government/policy makers which can be retrieved in official documents
• Commitment towards HTA from government/policy makers and it is expressed in official documents
• Public money (funding) is allocated to HTA as expressed in official documents
• Willingness to commit public money (funding) to HTA as expressed in official documents
• Support for HTA from several stakeholders, including, the medical profession as expressed in publicly available documents
• Organisational structure and institutional set-up in place. The achievement of legal support (i.e., policy statement or a specific law providing
for the institution of a new body or giving HTA functions to an existing organisation) is important in formalising HTA activities
• International network strategy available
• Availability of human resource development:
◦ Capability to carry out HTA, including medical disciplines, public health specialists, including epidemiologists, statisticians, psychologists,
biomedical engineers and economists [number]
◦ An ability to review international literature, including expertise in searching the internet
◦ HTA training opportunities are available
Per element:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Number of memberships of HTAi More than 10 members = 3
5–10 members = 2
1–5 members = 1
0 members = 0
Domain: Identification
Criterion: Early warning system of horizon scanning system in place
Indicators:
At least one agency/organisation in the country is a member of the International Information Network on New and Changing Health
Technologies - Euroscan (since. . .)
Yes = 4
No = 0
Presence of fulfilment of primary characteristics of early warning systems as described in a publicly available document:
• Information is targeted to stakeholders
• Independent of commercial and industrial influence
• Clearly defined pathway
Per characteristic:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Monitoring system(s) to identify technologies in need of assessment in place (e.g. registries, structured and standardized questionnaires,
databases)
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Other activities involving identification are performed – e.g. reviewing medical journals to identify technologies in need of assessment etc. Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
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Table 1. Continued
Score (on country level)
Domain: Priority setting
Criterion: System for setting priorities for HTA exists
Indicators:
Presence of fulfilment of characteristics of priority setting process for HTA as described in a publicly available document:
• Explicit and transparent process is in place that is replicable (criteria and procedures are well described)
• Process reflects the goals of the programme
• Stakeholder involvement is included
• Information on priorities is set
• Processes and outcomes of priority setting are evaluated
Per characteristic:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
System(s) in place to review the international evidence base (literature) to set priorities (knowledge of what has already been done) Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Domain: Assessment
Criterion: The goal and scope of the HTA should be explicit and relevant to its use
Indicator:
Clear description (e.g. in a start document/work plan) of
• health care problem(s)
• patient population
• practitioners or users
• health care setting(s) of care
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: HTA should include alternative technologies
Indicator:
Description and technical characteristics of health technology under study (e.g. pharmaceuticals, devices,
procedures, diagnostics, public health interventions and treatment) and its alternatives as well as current use - should be part of guideline on
how to undertake the planned HTA
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: HTA should assess safety and efficacy/effectiveness at the minimum
Indicator:
Description of the aspects of the problem to be addressed should be part of guideline on how to undertake the planned HTA:
• safety and clinical effectiveness
• cost and cost-effectiveness (economic considerations)
• ethical analysis
• organizational analysis
• social-cultural aspects
• legal aspects
Per aspect:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: HTA should incorporate standardised methods for assessing aspects under study
Indicators:
Collection of new primary data should be part of guideline on how to undertake the planned HTA Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Performance of systematic review / meta-analysis of all available evidence - should be part of guideline on how to undertake the planned HTA Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
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Table 1. Continued
Domain: Assessment
Criterion: HTA should incorporate standardised methods for assessing aspects under study
Indicators: Score (on country level)
Literature searches in different languages – using key HTA databases - should be part of guideline on how to undertake the planned HTA:
• HTA Database
• Medline/PubMed
• Cochrane Library
• Database of Abstracts of Reviews of Effects (DARE)
• Search engines
• HTA reports
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: Use an explicit and systematic approach to classify and critically appraise the quality of the available studies
Indicator:
Use of guidelines for systematic reviews (e.g., developed by the Centre for Reviews and Dissemination at the University of York) - should be part
of guideline on how to undertake the planned HTA
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: HTAs should consider and address issues of generalizability and transferability
Indicator:
Addressing generalizability and transferability - should be part of the guideline on how to undertake the planned HTA (e.g. EUnetHTA adaptation
toolkit)
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Domain: Appraisal
Criterion: Transparent and deliberative system for appraisal in place
Indicator:
Presence of fulfilment of characteristics of appraisal process as expressed in a publicly available document:
• Explicit and transparent process is in place that is replicable (procedures are well described)
• Specification of stakeholder involvement
• Mechanism(s) for appeal are in place
Per characteristic:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Domain: Reporting
Criterion: HTA should be an unbiased and transparent process
Indicator:
Use of guideline on best practice in undertaking and reporting HTA (ECHTA report) or INAHTA checklist for HTA reports Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: Publications
Indicators:
Number of HTA reports per year produced (total last year) and per institute) More than 12 (on average 1
per month) = 4
6–12 = 3
1–6 = 2
0 = 0
[If a country does not produce reports] Use of HTA reports produced by other countries Yes = 1
No = 0
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Table 1. Continued
Domain: Reporting
Criterion: Publications
Indicators: Score (on country level)
Number of HTA reports (total last year) that are produced by those who apply for reimbursement (i.e., paid for by a for profit organization) and
of which the quality is checked by another organization/institute)
More than 12 (on average 1
per month) = 4
6–12 = 3
1–6 = 2
0 = 0
Domain: Dissemination of findings and conclusions
Criterion: HTA should be performed in a timely manner
Indicator:
Information (HTA report) is disseminated to decision makers before the decision on a particular technology is made Always = 3
To a large extent = 2
To some extent = 1
Never = 0
Criterion: HTA findings need to be communicated to decision makers
Indicator:
Presence of fulfilment of characteristics of a publicly available dissemination strategy as expressed in a publicly available document:
• what is to be said, to whom it should be said, what way of communication should be used? (e.g. clear recommendations for target groups)
• Starting with the selection of the subject
• Involvement of advisory groups
Per characteristic:
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Domain: Implementation in policy and practice
Criterion: HTA should inform policy and practice
Indicators:
Legal mandate of the HTA agency/organisation involved in HTA in the health care system Yes = 1
No = 0
Existence of an administrative framework/ link to regulatory process as described in a publicly available document Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Availability of one or more implementation plans with attention to factors that influence implementation of HTA such as financial incentives,
regulation, physicians preferences, patient preferences
Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
Criterion: Measuring impact of HTA
Indicator:
System(s) in place to monitor and evaluate the impact of HTA Completely present = 3
Largely present = 2
Present to some extent = 1
Not present = 0
We targeted 449 key informants, representing Ministries of
Health, HTA agencies, university/research organizations, third
party payers, medical device industry, pharmaceutical industry,
and regulatory authorities. Potential respondents were identified
bymeans of our own networks, the survey database fromour for-
mer study (10), the HTAi annualmeeting in Brazil (2011), HTAi
Membership Directories (2010, 2008, and 2007), authors of rel-
evant articles, presenters at relevant conferences, and members
of NEVALAT (thematic network on the economic evaluation
of healthcare program and its application in decision making
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Table 2. Response Rate per Country
No. of Total no. No. of complete Response
Country invitees of responses responses rate
Argentina 18 2 2 11.1%
Brazil 72 19 18 26.4%
India 44 5 5 11.4%
Indonesia 27 2 1 7.4%
Malaysia 29 4 4 13.8%
Mexico 40 4 3 10.0%
Russia 20 4 4 20.0%
Australia 43 7 7 16.3%
Canada 51 12 12 23.5%
United Kingdom 41 6 5 14.6%
Total 385 65 61 16.9%
in Latin American countries). After correcting for bounces and
invitations sent to people with no or limited knowledge of the
subject, the final panel consisted of 385 persons.
The survey was distributed by email through Check Mar-
ket on September 30th 2011 and was live for completion until
November 4th 2011. To maximize response rates two reminders
were sent to respondents who had not or only partially com-
pleted the survey. Responses with at least 50 percent of the
survey completed were considered as partial and included for
analysis. The survey responses (65/385, see Table 2) were an-
alyzed by country using IBM SPPS Statistics (version 19.0 for
Windows).
Determining the Level of HTA
The information from the document review andWeb-based sur-
vey was used to determine the score for each criterion (see
Table 1). The scores were assigned by the lead author (WO) on
the basis of the answer given by the majority of the respondents
in a country, in conjunction with the evidence found in the lit-
erature. The scoring was reviewed by another researcher (PB).
Any disagreement was resolved in a consensus meeting. These
scores were then added resulting in a total score per domain.
These scores were reviewed by the other members of the project
team (H.V. and D.B.). We used this score for determining the
level of HTA in the countries selected and for benchmarking
purposes.
RESULTS
Institutionalization of HTA
The level of institutionalization is the highest in the reference
countries. These countries all obtained the maximum score of
28. Brazil has a comparable degree of institutionalization. The
institutionalization of HTA in Argentina, Mexico, andMalaysia
is lower, as these countries have a limited number of HTAi
members. Institutionalization is lowest in Russia, Indonesia,
and India as indicated by the lack of a formal HTA program, the
limited number of HTAi members, as well as lack of political
commitment to HTA (see Table 3).
In the countries with a formal HTA program, there is at
least one organization that is a member of INAHTA. They dif-
fer, however, in the way these agencies interact with providers
and purchasers of health care. Canada is complex, with sev-
eral programs at federal, provincial, and local levels. Also, in
Latin America (Argentina, Brazil, Mexico), more actors are
involved in decision making (11). In the countries where no for-
mal HTA program exists, decision making about the adoption
and use of health technologies may be carried out by health au-
thorities and health service providers. Decisions, however, are
frequently based on interests of individuals or “gut feelings.”
At best, decisions take into account experience generated in
other countries or selective expert advice. The challenge is to
shift to a decision-making process that follows the principles
such as those of evidence-based medicine, cost-effectiveness,
and patient centered services (5). With regard to institutional
set-up, both Indonesia and Russia have made some progress.
There is some, but limited, capacity available to search the In-
ternet and review international literature. In addition, there are
several training opportunities regarding pharmaco-economics
and outcomes research in India and Russia.
Identification of Health Technologies
We determined if a country has an early warning or horizon
scanning system in place. If not, we mapped the extent to which
earlywarning activities are carried out. Themaximum score that
could be obtained was 19. Australia, Canada, and the United
Kingdom have an early warning system(s) or horizon scanning
system(s) in place. For India, Mexico, and Russia, we found no
literature on identification of health technologies. Of the sur-
vey respondents from the middle-income countries, 75 percent
answered that at least one monitoring system to identify tech-
nologies is in place in their respective countries. For Argentina
and Brazil, we found evidence of such a system but not for
Indonesia and Malaysia. In Mexico and Russia, half of the re-
spondents do not think that such a monitoring system is present
in their country. More than half (55 percent) of the respondents
confirm the presence of other identification activities (such as
review of medical journals) described in a publicly available
document.
Priority Setting
We collected information on the existence of a priority set-
ting process including: (i) An explicit and transparent process
that is replicable (criteria and procedures); (ii) A process that
reflects the goals of (national, regional, local) health policy;
(iii) Attention to stakeholder involvement; (iv) Explicitly stated
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Table 3. Level of HTA Development per Domain
Country
Domain Argentina Brazil India Indonesia Malaysia Mexico Russia Australia Canada UK
Level of institutionalization 26 28 7 8 26 26 11 28 28 28
Identification of health technologies 3 4 1∗ 1 2 1∗ 1∗ 11 13 13
Priority setting 3 11 6∗ 6∗ 10 8 6∗ 11 12 18
Assessment 12 22 7∗ 13 22 23 10 26 28 31
Appraisal 0 4 0∗ 3 3 3∗ 0∗ 7 6 9
Reporting 7 9 2∗ 5∗ 4 7∗ 6∗ 11 11 11
Dissemination 4 6 1 4∗ 5 5 1∗ 8 8 11
Implementation 5 5 0∗ 4∗ 4 4 0∗ 7 7 8
∗Scoring mainly based on survey.
information on priorities; (v) and An evaluation of processes
and outcomes.
In addition, we identified countries that have a system for
reviewing international evidence (literature) to set priorities.
For each indicator, a maximum score of 3 could be obtained,
resulting in a total maximum score of 18.
We found a mixed picture with regard to the different el-
ements of a priority setting process (see Table 3). An explicit
system exists in Australia, Canada and the United Kingdom, as
well as in Brazil and Malaysia. We found limited evidence in
the literature on priority setting in India, Indonesia and Russia.
The majority of the survey respondents in all countries believe
that the process reflects the goals of health policy, that there is,
at least to some extent, stakeholder involvement and that the
information on priorities set is available. It appears that evalua-
tion is often not performed in the countries under study, except
in the United Kingdom and Brazil. This observation also ap-
plies to the presence of a system for reviewing the international
evidence base.
Assessment
A document describing a clear goal and scope of HTA is avail-
able in Australia, Canada, the United Kingdom, as well as in
Malaysia andMexico. All countries except India provide a clear
description of the safety and clinical effectiveness of the tech-
nology in their assessments. Cost and cost-effectiveness infor-
mation are well described in the reference countries, Brazil and
Mexico. The other aspects (ethical, organizational, social, and
legal aspects) are less examined, as in the rest of the world.
Argentina, Brazil, India, Indonesia, Mexico, and Russia
score low with regard to an explicit and systematic approach to
classify and critically appraise the quality of available studies.
Generalizability and transferability are not well described in
Argentina, Indonesia, Russia, and Mexico.
According to the survey results, the collection of new pri-
mary data is well described inAustralia, theUnitedKingdom, as
well as in Brazil. Conducting systematic reviews / meta-analysis
is covered in the reference countries and in Brazil and Mexico.
This also applies to literature searches in different languages,
which are also described in Malaysia (see Table 3). For each
of the 13 indicators reflecting the assessment phase, a maxi-
mum score of 3 could be obtained. This means that in total each
country could obtain a score of 39.
Appraisal
The concept of appraisal was consolidated and formalized with
the establishment of theNational Institute ofHealth andClinical
Excellence in 1999. Appraisal is a consideration of the outputs
of the assessment process within the context of additional infor-
mation supplied by relevant parties. Although appraisal is often
not separated from the assessment phase, we tried to identify
whether a transparent and deliberative system exists. In total,
countries could obtain a maximum score of 9. It appears that
the reference countries all have appraisal systems in place, al-
though there is some criticism regarding transparency of these
systems in Canada. Also, Brazil is taking steps toward a more
explicit process of decisionmaking.Argentina, India andRussia
do not have a clear and transparent system in place. Indonesia,
Malaysia, and Mexico have some elements of an appraisal sys-
tem (see Table 3).
Reporting
With regard to the reporting of HTA information, we examined
whether reporting is unbiased and according to a transparent
process. Also, we identified the total number of HTA reports
produced annually using public resources and the total num-
ber of HTA reports produced by applicants for reimbursements.
With regard to these indicators, countries could obtain a maxi-
mum score of 11.
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In all countries, except for India and Russia, it appears that
there is at least one agency/organization that uses (some sort
of) guidelines on reporting (e.g., ECHTA report or INAHTA
checklist for HTA reports). In Australia, Canada, and the United
Kingdom, several HTA reports (i.e., more than twelve reports
per year) are published on an annual basis, which is likely due to
a well-established HTA infrastructure in those countries. This
also includes a relatively high number of reports produced by
applicants for reimbursement (i.e., more than twelve reports per
year) (see Table 3). We found similar results for Brazil.
Dissemination
HTA information needs to be timely and effectively communi-
cated to be valuable for decision makers. A publicly available
dissemination strategy is important. We, therefore, examined
whether the information (HTA report) is disseminated to deci-
sion makers before the decision on a particular technology is
made (see Table 1). The maximum score for each of the indi-
cators was 3, which totals the maximum score to 12 for this
domain.
Dissemination strategies are well developed in the reference
countries, and to a lesser extent in Brazil, Argentina, Malaysia,
Mexico, and Indonesia. This might be due to the existence of
HTA agencies or HTA unit(s) in those countries. More than
80 percent of survey respondents state that clear recommen-
dations for target groups are at least to some extent present in
publicly available dissemination strategies. Clear information
on dissemination strategies in India and Russia is lacking (see
Table 3).
Implementation in Policy and Practice
HTA tends to have a higher profile in coverage decision making
when these processes are explicit, deliberative and formalized
(i.e., HTA is integrated and enforced by law). We examined
whether (a) at least one organization involved in HTA has a legal
mandate in the healthcare system, (b) there is a link between
HTA and the regulatory process, and (c) an implementation plan
is used. In addition, we looked at the extent to which the actual
impact of HTA is measured.
Almost 63 percent of the survey respondents believe that
HTA organizations in their countries have a legal mandate.
In the literature, we found evidence for such a mandate
in the reference countries, Argentina, Brazil, Indonesia, and
Mexico.
There is a clear link between HTA and a regulatory frame-
work in the reference countries as well as in Argentina, Brazil,
and Malaysia. The other countries showed divergent outcomes,
although the majority believes that there is a link between HTA
and the regulatory process, with the exception of Russia and
India. This was also confirmed by the literature.
Regarding implementation plans, almost 90 percent of the
respondents state that factors influencing the implementation of
HTA are taken into account when HTA is used in their country,
at least to some extent. However, this does not apply to India
and Russia (see Table 3).
Measuring the impact of HTA is becoming more frequent
in the HTA community. However, only a few studies have been
undertaken to better understand the issue (1,10). Measuring
HTA impact by using monitoring systems is currently most
advanced in the reference countries.
For this domain, a maximum score of 10 could be obtained
(see Table 1).
DISCUSSION
With this study, we go beyond previous studies on the orga-
nization of HTA by focusing on a more systematic evaluation
of the level and trends in HTA development at country level,
taking into account the characteristics of the healthcare sys-
tem. Of particular interest is Brazil, which is developing rapidly
toward the standards of best practice in HTA. Political com-
mitment in Argentina and Mexico will determine how quickly
these countries can further develop and how the actions al-
ready undertaken will have an impact. For Malaysia, the main
challenge is to sustain the established HTA framework while
training (new) personnel. Indonesia has taken some steps to-
ward developing HTA capacity, although the focus is mainly
on pharmaco-economics. India and Russia are still at the very
beginning of introducing HTA in their countries. Political will is
obviously important for introducing and maintaining HTA in a
country.
There are strengths and weaknesses to our approach. A
strength is that we received minor comments from relevant
stakeholders and respondents during the development and ad-
justment phases of the instrument. These focused on the level at
which HTA should be mapped in each country: national and/or
provincial level and/or local (e.g., Canada).
One of the restrictions of this research lies in the scope of
the literature retrieved (limited to publications that are available
in English). A Web-based survey was performed to collect ad-
ditional information for each country to support and enrich the
profiles with information which is not publicly available.
Implementing the survey highlighted several challenges.
First, we address the issue of identifying key persons working
in the HTA field. For countries with more established HTA ac-
tivities (e.g., Brazil), it was easier to identify a large number of
contact persons compared with countries with less established
HTA activities (e.g., Malaysia, Indonesia, India, and Russia).
Second, the initial response rate of the survey was relatively
low. We found that this was partly due to the fact that our sur-
vey was likely distributed as SPAM (with survey as a trigger
word). Efforts have been made to ensure a good response rate,
with reminder emails sent 10 days after the first invitation was
launched to all those stakeholders who had not responded to
the survey. Reminders were also sent to stakeholders on the
panel who had only partially responded to the survey, 1 day
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after their survey was received. A subsequent reminder was
sent to all stakeholder panel members who had not responded
as we suspected that our survey had been filtered as SPAM.
After sending the reminder, we expected the response rate to
increase. As we encountered no significant increase in response
rate, we decided to search for additional contact information.
After sending a second reminder through our own system, it
was found that a large number (n = 52) of the initial email
addresses were bounced. As a result, we decided to sent a final
reminder to contacts from countries with a very low response
and to contactswith corrected email addresses (n= 82). Further-
more, the nonresponse in most countries with less established
HTA activities was relatively higher than in other countries.
This might be explained by a lack of interest for the subject or
people considering themselves not ‘qualified enough’ to answer
the survey. Another issue related to the relatively low response
rate could be the language barrier (e.g., in Argentina, Brazil,
Malaysia, Mexico, Russia, and Indonesia). Also, a few respon-
dents indicated that they had difficulties with the phrasing of the
questions. In addition, we found that the results of the survey
demonstrated sometimes contradictory views regarding several
questions and often conflicted with the evidence retrieved from
other sources, especially for the developing countries. For some
of these countries, HTA activities are rather new (e.g., India,
Indonesia, and Russia). In other cases, the number of survey
respondents was relatively low for some of the countries (e.g.,
Argentina, India, Indonesia, andMexico). In general, the survey
scores for Canada appeared to be relatively low compared with
the other reference countries. This might be explained by the
fragmentation in the HTA process in Canada; it was not always
clear whether the respondent related to the federal or provincial
perspective. The low number of respondents has implications
for the reliability of the findings from the survey. For future use,
it is necessary to require a minimum number of informants per
country.
Another limitation of the study is the assignment of scores
using desk research and survey as main sources. Although for
some indicators the evidence is clear (e.g. membership of IN-
AHTA, EuroScan), for others (e.g., (elements of a) system for
priority setting) it was less clear. In these cases, we used the
experiences of the project team, but this might result in an over-
or underestimation of the score for each country. Taking these
limitations into account, we base our summarizing conclusions
mainly on the findings from the document review.
CONCLUSIONS
Mapping of HTA at the country level is feasible and can be done
by focusing on the level of institutionalization and the process
of HTA. This includes the identification, priority setting, assess-
ment, appraisal, reporting, dissemination, and implementation
of HTA results in policy and practice.
The results of this first mapping exercise can be used as a
baseline measurement for future evaluation. It would be ben-
eficial to evaluate how the different selected countries would
score on the different indicators after 3–5 years (especially those
countries that have announced healthcare reforms and changes
in the HTA processes). Ideally, progress should be monitored on
a regular basis to identify trends in the indicators (e.g., publica-
tion of reports and HTAi memberships could be monitored on a
yearly basis). This can help different actors (governments, HTA
organizations, industry, other stakeholders) to assess the devel-
opment of HTA at country level, help inform HTA strategies,
and justify expenditure for HTA.
The selection of countries includes both lower-middle-
income countries and upper-middle-income countries from dif-
ferent regions. This strengthens the argument that the instrument
can be applied to other middle-income countries and probably
low-income countries too. Before applying the instrument to
other countries, it needs, however, further validation.
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